1. The total number of prelaryngeal and pretracheal lymph node metastases: is it a reliable predictor of contralateral central lymph node metastasis in papillary thyroid carcinoma?
作者: Qiang Chen.;Tao Wei.;Xun-Li Wang.;Zhi-Hui Li.;Zhen-Hong Du.;Jing-Qiang Zhu.
来源: J Surg Res. 2017年214卷162-167页
Central lymph node (CLN) metastasis in papillary thyroid carcinoma (PTC) is common and being able to predict CLN metastasis helps surgeons determine individualized therapy. However, the relationship between contralateral CLN metastasis and the total number of positive lymph nodes (LNs) in the combined prelaryngeal and pretracheal region remains unclear. This study aimed to investigate whether the total number of positive LNs in the combined prelaryngeal and pretracheal region has clinical significance as a predictor for contralateral CLN metastasis.
2. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
作者: Malcolm Mason.;Pierre Richaud.;Zsolt Bosnyak.;Anders Malmberg.;Anders Neijber.
来源: Low Urin Tract Symptoms. 2017年9卷2期82-88页
In patients with prostate cancer (PCa), prostate enlargement may give rise to lower urinary tract symptoms (LUTS); many patients suffer from moderate-to-severe symptoms. We compare the efficacy of degarelix and goserelin plus bicalutamide in improving LUTS in PCa patients.
3. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
作者: Chan Y Cheah.;Loretta J Nastoupil.;Peter McLaughlin.;Michelle A Fanale.;Sattva S Neelapu.;Luis E Fayad.;Frederick B Hagemeister.;Nathan H Fowler.
来源: Br J Haematol. 2016年175卷3期531-533页 4. A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months.
作者: Takayuki Nose.;Yuki Otani.;Shuuji Asahi.;Iwao Tsukiyama.;Takushi Dokiya.;Toshiaki Saeki.;Ichirou Fukuda.;Hiroshi Sekine.;Naoto Shikama.;Yu Kumazaki.;Takao Takahashi.;Ken Yoshida.;Tadayuki Kotsuma.;Norikazu Masuda.;Eisaku Yoden.;Kazutaka Nakashima.;Taisei Matsumura.;Shino Nakagawa.;Seiji Tachiiri.;Yoshio Moriguchi.;Jun Itami.;Masahiko Oguchi.
来源: Breast Cancer. 2016年23卷6期861-868页
A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy was performed. The first clinical results were reported with a median follow-up of 26 months.
5. Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
作者: Ayaka Shimo.;Koichiro Tsugawa.;Seiko Tsuchiya.;Reiko Yoshie.;Kyoko Tsuchiya.;Tomoko Uejima.;Yasuyuki Kojima.;Arata Shimo.;Ryosuke Hayami.;Toru Nishikawa.;Yukari Yabuki.;Hisanori Kawamoto.;Akihiko Sudo.;Mamoru Fukuda.;Yoshihide Kanemaki.;Ichiro Maeda.
来源: Breast Cancer. 2016年23卷6期851-860页
Nipple-sparing mastectomy (NSM) is an advantageous treatment option, providing a complete cure and good cosmetic results. We tested whether NSM is a surgically and oncologically safe technique.
6. CT perfusion imaging of the stomach: a quantitative analysis according to different degrees of adenocarcinoma cell differentiation.
作者: Sun Zongqiong.;Li Xiaohong.;Cai Wei.;Zhou Jiangfeng.;Ge Yuxi.;Xie Zhihui.;Jin Linfang.;Pu Yong.;Yan Gen.
来源: Clin Imaging. 2016年40卷3期558-62页
To evaluate clinical usefulness of computed tomography perfusion imaging (CTPI) in gastric cancer.
7. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.
作者: Lawrence R Kleinberg.;Paul J Catalano.;Arlene A Forastiere.;Steven M Keller.;Edith P Mitchel.;Pramila Rani Anne.;Al B Benson.
来源: Int J Radiat Oncol Biol Phys. 2016年94卷4期738-46页
Toxicity, pathologic complete response, and long-term outcomes are reported for the neoadjuvant therapies assessed in a randomized phase 2 Eastern Cooperative Oncology Group and American College of Radiology Imaging Network trial for operable esophageal adenocarcinoma, staged as II-IVa by endoscopy/ultrasonography (EUS).
8. Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers.
作者: V Patil.;A Karpe.;V Noronha.;A Joshi.;V Muddu.;A Bhattacharjee.;S Dhumal.;K Prabhash.
来源: Indian J Cancer. 2015年52卷4期629-31页
Oral tyrosine kinase inhibitor (gefitinib and erlotinib) have been used in the palliative treatment of head and neck cancers with limited success. In this report, we aim to quantify the symptomatic benefit, progression-free survival (PFS) and overall survival (OS) when erlotinib is given as second-line treatment in Head and neck cancers.
9. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer.
作者: Maryam Moteabbed.;Alexei Trofimov.;Gregory C Sharp.;Yi Wang.;Anthony L Zietman.;Jason A Efstathiou.;Hsiao-Ming Lu.
来源: Int J Radiat Oncol Biol Phys. 2016年95卷1期444-453页
To quantify and compare the impact of interfractional setup and anatomic variations on proton therapy (PT) and intensity modulated radiation therapy (IMRT) for prostate cancer.
10. Role of neo-adjuvant chemotherapy in locally advanced breast cancer.
Locally advanced breast cancer (LABC) is common in developing countries. The advancement of disease leads to decreased probability of radical cure and increase in treatment cost. The study evaluated neo adjuvant chemotherapy with MRM and MRM followed by adjuvant chemotherapy and also the effectiveness of neo-adjuvant chemotherapy in down staging advanced disease and offering radical cure.
11. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
作者: Shin Kobayashi.;Goro Honda.;Masanao Kurata.;Yukihiro Okuda.;Katsunori Sakamoto.;Katsuyuki Karasawa.;Tachen Chang.;Naoto Egawa.;Terumi Kamisawa.;Yasushi Omuro.;Koji Tsuruta.
来源: Hepatogastroenterology. 2015年62卷140期1031-6页
To determine the recommended dose (RD) for full-dose S-1 and low-dose gemcitabine combined with radiotherapy in patients with non-metastatic advanced pancreatic cancer.
12. CT colonography for the detection of nonpolypoid colorectal lesions A prospective series.
作者: Gian Luca Baiocchi.;Giancarlo Mazzarri.;Luigi Totaro.;Guido Missale.;Federico Gheza.;Mario Morone.;Barbara Frittol.;Dario Moneghini.;Guido Tiberio.;Sarah Molfino.;Luigi Graziol.;Nazario Portolani.
来源: Ann Ital Chir. 2015年86卷532-8页
To determine the diagnostic accuracy of CT-colonography (CTC) for colorectal nonpolypoid lesions.
13. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
作者: Sun Min Lim.;Byoung Chul Cho.;Sang-We Kim.;Seok Yun Kang.;Dae Seog Heo.;Heung Tae Kim.;Dae Ho Lee.;Dong-Wan Kim.;Minkyu Jung.;Jin-Hyuk Choi.;Hyo Sup Shim.;Jong Rak Choi.;Joo-Hang Kim.
来源: Lung Cancer. 2016年93卷1-8页
Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
14. Comparison of clinicopathological features of gastric carcinoma, between 2 times periods, at a single institute in China.
作者: Chen Jianhui.;He Yulong.;Chen Chuangqi.;Wu Kaiming.;Zhang Xinhua.;Cai Shirong.
来源: J Cancer Res Ther. 2015年11卷4期874-81页
This study aims to compare the clinicopathological features of gastric carcinoma between two different time periods, and to investigate the prognostic factors for gastric carcinoma.
15. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
作者: Manoj Gupta.;Rohit Mahajan.;Vikrant Kaushal.;Rajeev K Seem.;Manish Gupta.;Tapesh Bhattacharyya.
来源: J Cancer Res Ther. 2015年11卷4期723-9页
Concurrent chemoradiation (CCRT) is currently considered to be the standard of care in locally advanced head and neck cancer. The optimum radiotherapy schedule for best local control and acceptable toxicity is not yet clear. We aimed at shortening of treatment time by using accelerated radiation, thereby comparing the disease response, loco-regional tumor control and tolerability of accelerated radiation (six fractions per week) against CCRT in locally advanced head and neck cancer.
16. Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study.
作者: Mutahir Ali Tunio.;Mushabbab Al Asiri.;Yasser Bayoumi.;Laura G Stanciu.;Naji Al Johani.;Eyad Fawzi Al Saeed.
来源: J Cancer Res Ther. 2015年11卷4期684-9页
Aim was to evaluate the dose distribution within the thyroid gland its association with hypothyroidism in breast cancer (BC) patients receiving supraclavicular (SC) radiation therapy (RT).
17. Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.
作者: Anthony Brade.;Robert MacRae.;Scott A Laurie.;Andrea Bezjak.;Ronald Burkes.;Quincy Chu.;John R Goffin.;John Cho.;Andrew Hope.;Alex Sun.;Natasha Leighl.;Stephanie Capobianco.;Ronald Feld.;Essai Mahalingam.;Anwar Hossain.;Neill Iscoe.;Frances A Shepherd.
来源: Clin Lung Cancer. 2016年17卷2期133-41页
Concurrent thoracic radiation and platinum-based chemotherapy is the standard of care for treatment of unresectable stage IIIA-IIIB non-small-cell lung cancer (NSCLC), but the optimal drug regimen has not been established.
18. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
作者: Aaron T Wild.;Joseph M Herman.;Avani S Dholakia.;Shalini Moningi.;Yao Lu.;Lauren M Rosati.;Amy Hacker-Prietz.;Ryan K Assadi.;Ali M Saeed.;Timothy M Pawlik.;Elizabeth M Jaffee.;Daniel A Laheru.;Phuoc T Tran.;Matthew J Weiss.;Christopher L Wolfgang.;Eric Ford.;Stuart A Grossman.;Xiaobu Ye.;Susannah G Ellsworth.
来源: Int J Radiat Oncol Biol Phys. 2016年94卷3期571-9页
Radiation-induced lymphopenia (RIL) is associated with inferior survival in patients with glioblastoma, lung cancer, and pancreatic cancer. We asked whether stereotactic body radiation therapy (SBRT) decreases severity of RIL compared to conventional chemoradiation therapy (CRT) in locally advanced pancreatic cancer (LAPC).
19. Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance).
作者: Bruce G Haffty.;Linda M McCall.;Karla V Ballman.;Sarah McLaughlin.;Reshma Jagsi.;David W Ollila.;Kelly K Hunt.;Thomas A Buchholz.;Judy C Boughey.
来源: Int J Radiat Oncol Biol Phys. 2016年94卷3期493-502页
American College of Surgeons Oncology Group Z1071 was a prospective trial evaluating the false negative rate of sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial node-positive disease. Radiation therapy (RT) decisions were made at the discretion of treating physicians, providing an opportunity to evaluate variability in practice patterns following NAC.
20. NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
作者: Mehran Ghasemzadeh.;Ehteramolsadat Hosseini.;Anthony P Schwarer.;Ali Akbar Pourfathollah.
来源: Leuk Res. 2016年43卷58-65页
NK cell cytotoxicity against residual leukemic cells is crucial for immune system reconstitution after hematopoietic stem cell transplantation (HSCT). Since immune recovery after transplant still remains a major concern, we studied the counterbalance of NK cell receptors after HSCT and its importance in NK cell functional recovery. We investigated NK cell reconstitution in 27 acute leukemia patients at different time points following HLA-matched allogeneic HSCT compared to those of donors. NK cells were evaluated for their cytotoxicity in a standard (51)Cr-release assay against target cells and also analyzed for their receptors expression using flow cytometry. Early after transplant, we found higher percentage of CD56(bright) NK cells, increased levels of NKG2A and NCRs as well as decreased levels of KIRs expression on NK cells associated with an impaired cytotoxicity of these cells. All the abnormalities were normalized by one year after HSCT when CD56(bright) NK cells gradually differentiated into CD56(dim) subset. Collectively, we confirmed a gradual increase of CD56(dim) NK cells expressing NCRs with the significant decrease in NKG2A expression on NK cells. This finding was also associated with the recovery of NK cell cytotoxicity that suggests an important role for the kinetics of NK cell receptors during cell maturation in HSCT outcome.
|